Drug General Information
Drug ID
D0M4PH
Former ID
DIB009174
Drug Name
LOXO-101
Indication Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] Approved [1]
Company
Array biopharma; loxo oncology
Target and Pathway
Target(s) BDNF/NT-3 growth factors receptor (TrkB) Target Info Inhibitor [2]
NT-3 growth factor receptor (TrkC) Target Info Inhibitor [3]
Tropomyosin-related kinase A (TrkA) Target Info Inhibitor [1], [4]
KEGG Pathway MAPK signaling pathway
Neurotrophin signaling pathway
Alcoholism
Neurotrophin signaling pathway
Inflammatory mediator regulation of TRP channels
Pathways in cancer
Transcriptional misregulation in cancer
Thyroid cancer
Central carbon metabolism in cancer
NetPath Pathway IL2 Signaling Pathway
Pathway Interaction Database SHP2 signaling
Posttranslational regulation of adherens junction stability and dissassembly
Neurotrophic factor-mediated Trk receptor signaling
Reactome NGF-independant TRKA activation
NGF-independant TRKA activation
PI3K/AKT activation
PI3K/AKT activation
WikiPathways SIDS Susceptibility Pathways
BDNF signaling pathway
Integrated Pancreatic Cancer Pathway
NGF signalling via TRKA from the plasma membrane
References
REF 1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
REF 2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1818).
REF 3 ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. Clin Adv Hematol Oncol. 2014 Jul;12(7):429-39.
REF 4 Clinical pipeline report, company report or official report of Loxo Oncology.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Wang and Dr. Li.